DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Information source: Asociación para Evitar la Ceguera en México
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Macular Edema; Central Retinal Vein Occlusion

Intervention: bevacizumab and triamcinolone (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Asociación para Evitar la Ceguera en México

Official(s) and/or principal investigator(s):
Carmen Gonzalez-Mijares, Physician, Principal Investigator, Affiliation: APEC
Hugo Quiroz-Mercado, Retinologyst, Study Director, Affiliation: APEC
Juan Manuel Jimenez Sierra, Retinologyst, Study Chair, Affiliation: APEC
MA Martinez-Castellanos, Physician, Study Chair, Affiliation: APEC
Octavio Burgos Vejar, Physician, Study Chair, Affiliation: APEC
Raul Velez-Montoya, Physician, Study Chair, Affiliation: APEC
Ma de Lourdes Lopez Ramos, Physician, Study Chair, Affiliation: APEC
Omar Honerlager, preresident, Study Chair, Affiliation: APEC

Overall contact:
Carmen Conzalez-Mijares, Physician, Phone: 5517638245, Email: cacegomi@hotmail.com

Summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Clinical Details

Official title: Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Changes in Best corrected visual acuity and macular edema measured with OCT

Secondary outcome: Report treatment complications

Detailed description: Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Macular edema secondary to central retinal vein occlusion

- BCVA worse than 20/40

- Central macular >250 mc with OCT

Exclusion Criteria:

- Diabetic retinopathy or other retinopathy

- Media opacity that does not allow following

- steroid responder

- diagnosed glaucoma or IOP > 21 mmHg

Locations and Contacts

Carmen Conzalez-Mijares, Physician, Phone: 5517638245, Email: cacegomi@hotmail.com

Asociacion Para Evitar la Ceguera en Mexico, Mexico city, Coyoacan 04030, Mexico; Recruiting
Retina Department, Phone: 5510841400, Ext: 1171, Email: retinamex@yahoo.com
Additional Information

Starting date: June 2007
Last updated: November 30, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017